IL5 and COVID-19: <h4>Background</h4>We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response.<h4>Methods</h4>She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021.